These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 20129150)

  • 1. Diagnosis and management of antiretroviral-therapy failure in resource-limited settings in sub-Saharan Africa: challenges and perspectives.
    Harries AD; Zachariah R; van Oosterhout JJ; Reid SD; Hosseinipour MC; Arendt V; Chirwa Z; Jahn A; Schouten EJ; Kamoto K
    Lancet Infect Dis; 2010 Jan; 10(1):60-5. PubMed ID: 20129150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extraordinary heterogeneity of virological outcomes in patients receiving highly antiretroviral therapy and monitored with the World Health Organization public health approach in sub-saharan Africa and southeast Asia.
    Aghokeng AF; Monleau M; Eymard-Duvernay S; Dagnra A; Kania D; Ngo-Giang-Huong N; Toni TD; Touré-Kane C; Truong LX; Delaporte E; Chaix ML; Peeters M; Ayouba A;
    Clin Infect Dis; 2014 Jan; 58(1):99-109. PubMed ID: 24076968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tackling virological failure in HIV-infected children living in Africa.
    Jenabian MA; Costiniuk CT; Mboumba Bouassa RS; Chapdeleine Mekue Mouafo L; Brogan TV; Bélec L
    Expert Rev Anti Infect Ther; 2015; 13(10):1213-23. PubMed ID: 26204960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
    Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
    J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges in implementing HIV laboratory monitoring in resource-constrained settings: how to do more with less.
    Bélec L; Bonn JP
    Future Microbiol; 2011 Nov; 6(11):1251-60. PubMed ID: 22082287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa.
    Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; Rinke de Wit TF;
    J Infect Dis; 2012 Jun; 205(11):1739-44. PubMed ID: 22448003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-Line Antiretroviral Therapy in Sub-Saharan Africa: It Is Time to Mind the Gaps.
    Murphy RA; Court R; Maartens G; Sunpath H
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1181-1184. PubMed ID: 28793781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
    van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
    J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characteristics and response to antiretroviral therapy of HIV-1-infected patients born in Africa and living in France.
    Breton G; Lewden C; Spire B; Salmon D; Brun-Vézinet F; Duong M; Allavena C; Leport C; Salamon R;
    HIV Med; 2007 Apr; 8(3):164-70. PubMed ID: 17461860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early initiation of antiretroviral therapy and universal HIV testing in sub-Saharan Africa: has WHO offered a milestone for HIV prevention?
    Menon S
    J Public Health Policy; 2010 Dec; 31(4):385-400. PubMed ID: 21119646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.
    Sungkanuparph S; Win MM; Kiertiburanakul S; Phonrat B; Maek-a-nantawat W
    Int J STD AIDS; 2012 May; 23(5):316-8. PubMed ID: 22648883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of laboratory monitoring for management of HIV treatment in sub-Saharan Africa: a model-based analysis.
    Hamers RL; Sawyer AW; Tuohy M; Stevens WS; Rinke de Wit TF; Hill AM;
    AIDS; 2012 Aug; 26(13):1663-72. PubMed ID: 22695297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria.
    van Oosterhout JJ; Brown L; Weigel R; Kumwenda JJ; Mzinganjira D; Saukila N; Mhango B; Hartung T; Phiri S; Hosseinipour MC
    Trop Med Int Health; 2009 Aug; 14(8):856-61. PubMed ID: 19552661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral therapy in sub-Saharan Africa.
    Müller O; Corrah T; Katabira E; Plummer F; Mabey D
    Lancet; 1998 Jan; 351(9095):68. PubMed ID: 9433449
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV pharmacotherapy issues, challenges, and priorities in sub-Saharan African countries.
    Maponga CC; Ma Q; Slish JC; Morse GD
    Top HIV Med; 2007; 15(3):104-10. PubMed ID: 17598930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress with Scale-Up of HIV Viral Load Monitoring - Seven Sub-Saharan African Countries, January 2015-June 2016.
    Lecher S; Williams J; Fonjungo PN; Kim AA; Ellenberger D; Zhang G; Toure CA; Agolory S; Appiah-Pippim G; Beard S; Borget MY; Carmona S; Chipungu G; Diallo K; Downer M; Edgil D; Haberman H; Hurlston M; Jadzak S; Kiyaga C; MacLeod W; Makumb B; Muttai H; Mwangi C; Mwangi JW; Mwasekaga M; Naluguza M; Ng'Ang'A LW; Nguyen S; Sawadogo S; Sleeman K; Stevens W; Kuritsky J; Hader S; Nkengasong J
    MMWR Morb Mortal Wkly Rep; 2016 Dec; 65(47):1332-1335. PubMed ID: 27906910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistently high IgA serum levels are a marker of immunological or virological failure of combined antiretroviral therapy in children with perinatal HIV-1 infection.
    Chiappini E; Galli L; Tovo PA; Gabiano C; de Martino M;
    Clin Exp Immunol; 2005 May; 140(2):320-4. PubMed ID: 15807857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.